Global Bronchiectasis Drugs Market Is Estimated To Witness High Growth Owing To Rising Prevalence of Chronic Respiratory Diseases and Increasing R&D Investments
The bronchiectasis drugs market is estimated to be valued at US$ 303.8 million in 2023 and is expected to exhibit a CAGR of 10% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: Bronchiectasis is a chronic respiratory disease characterized by the enlargement and inflammation of the airways in the lungs. This condition leads to the accumulation of mucus, bacterial infection, and frequent respiratory symptoms such as coughing, wheezing, and shortness of breath. The bronchiectasis drugs market offers pharmaceutical products and therapies that aim to manage and treat this condition effectively. The market is driven by the increasing prevalence of chronic respiratory diseases, including bronchiectasis, and the growing demand for effective therapeutic options. Market Dynamics: The bronchiectasis drugs market is driven by two main factors. Firstly, the rising prevalence of chronic respiratory diseases, particularl...